Lundbeck has announced plans to to investigate Lu AA21004 for the treatment of depression in patients and will enrol the first patient in a 400 patient Phase II study by the end of third quarter 2006. The decision is based on positive pre-clinical results as well as positive
conclusion of the Phase I trials in healthy individuals.
Lu AA21004 is
the most advanced project in Lundbeck within a new chemical class, the bis-aryl-sulphanyl
amines. The pharmacology of these projects is markedly different from any currently
marketed antidepressants.
Compared with currently approved antidepressants
preclinical models have demonstrated Lu AA21004 to address important unmet needs
for patients on both fast onset of effect and increased efficacy.
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
J&J Enters Robotic Surgery Market
The companies entered into a cooperative agreement in May 2018 to combine J&J’s NeuWave system with the Monarch platform.
CDER’s Regulatory Modernization Will Peak in 2019, Woodcock Says
The center expects to have its proposed reorganization approved by HHS towards the end of FY 2019.
